# Evaluation of BRC-002 Safety, Tolerability, Pharmacokinetics, and Food Effects in Healthy Participants

> **NCT07699120** · PHASE1 · ENROLLING_BY_INVITATION · sponsor: **Biopharmaceutical Research Company** · enrollment: 50 (estimated)

## Conditions studied

- Healthy Adult Participants

## Interventions

- **DRUG:** BRC-002
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07699120
- **Lead sponsor:** Biopharmaceutical Research Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2026-06-15
- **Primary completion:** 2026-10
- **Final completion:** 2026-11
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2026-07-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07699120

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07699120, "Evaluation of BRC-002 Safety, Tolerability, Pharmacokinetics, and Food Effects in Healthy Participants". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07699120. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*